Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.

Published

Journal Article

PURPOSE: Vascular endothelial growth factor (VEGF) expression is prognostic in melanoma, and the activity of VEGF is mediated in part through the receptor tyrosine kinase Flk-1. A Phase II study of SU5416, a preferential inhibitor of Flk-1, was carried out in patients with metastatic melanoma to determine clinical response, tolerability, and changes in tumor vascular perfusion. EXPERIMENTAL DESIGN: Patients with documented progressive disease and

Full Text

Cited Authors

  • Peterson, AC; Swiger, S; Stadler, WM; Medved, M; Karczmar, G; Gajewski, TF

Published Date

  • June 2004

Published In

Volume / Issue

  • 10 / 12 Pt 1

Start / End Page

  • 4048 - 4054

PubMed ID

  • 15217937

Pubmed Central ID

  • 15217937

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.ccr-03-0766

Language

  • eng